Medtech firms demand more say in EU human tissue debate
This article was originally published in Clinica
Executive Summary
Calls for the European Commission to set up a tissue engineering regulatory body have led to fears among the medical device industry that the pharmaceutical sector could gain too much regulatory control. Proposals concerning the regulatory oversight of human tissue products just published by the European Commission's Scientific Committee on Medicinal Products and Medical Devices (SCMPMD)* have prompted the concerns with companies seeing oversight slipping towards the European Medicines Evaluation Agency.